BioSpace News Archive

ScreenPro Security Inc. (CSE: SCRN) (“ScreenPro” or the “Company”) is pleased to announce launching the Company’s concierge medical services (“Concierge”) offering home visit care starting in Vancouver to capitalize on the lucrative custom care management market.

The software as a medical device market is expected to reach USD 86,451.62 million by 2027 from US$ 18,488.00 Mn in 2019; it is estimated to grow at a CAGR of 21.9% during 2020–2027.

ARCA biopharma, Inc. today announced that Thomas Keuer , Chief Operating Officer, will present at the Access to Giving Virtual Investor Conference, which is being held virtually July 13-15, 2021.

Reneo Pharmaceuticals, Inc. announced today that Jefferies LLC, SVB Leerink LLC and Piper Sandler, as the representatives of the several underwriters of Reneo’s initial public offering, have agreed to waive the lock-up restriction with respect to 111,736 shares of common stock held by Wendy Johnson.

Genetic Technologies Limited today announced updates on the development of its Predictive Panel Risk Test designed to cover six different cancers including breast and colorectal cancer, prostate and ovarian cancer, pancreatic cancer and melanoma.

I-Mab today announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.

Foghorn Therapeutics Inc. today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

- Three-year overall allograft survival was 84% in crossmatch positive patients treated with imlifidase - In patients with a cPRA of ≥99.9%, three-year allograft survival was 92% - Data published in an article accepted by the American Journal of Transplantation

Astellas Pharma Inc. and Seagen Inc. announced the U.S. Food and Drug Administration granted PADCEV® regular approval in the U.S., in addition to approving a new indication for adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.

Perspectum is pleased to announce that a new prospective, observational, cohort study called Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing is underway.